News Search Results
Jan 23, 2025, 06:00 ET Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation
we're thrilled to be Flagship's UK academic partner." "Research collaborations like this can further propel the UK's position as a hub for biotechnology innovation," said Sir Tony Kouzarides, Director of the Milner Therapeutics Institute. "We are pleased to add Flagship's
More news about: Flagship Pioneering
Jan 22, 2025, 20:16 ET Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action
(NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
More news about: Robbins LLP
Jan 22, 2025, 20:12 ET Shareholder Rights Law Firm Robbins LLP Reminds RVNC Shareholders with Large Losses to Seek Counsel for the Revance Therapeutics, Inc. Class Action
(NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
More news about: Robbins LLP
Jan 22, 2025, 18:30 ET GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC
offering innovative cell therapies to improve patient outcomes across borders and establishing a competitive edge in the rapidly evolving global biotechnology landscape.
More news about: GC Cell
Jan 22, 2025, 17:31 ET Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Shanghai Jiatan Pharmatech, Sequella, Inc., LegoChem Biosciences, GlaxoSmithKline, BioVersys, BioNTech, SENTAN Pharma, ViChem, A&J Science, PDS Biotechnology, and others are evaluating new tuberculosis drugs to improve the treatment landscape.Promising tuberculosis pipeline therapies such
More news about: DelveInsight Business Research, LLP
Jan 22, 2025, 14:11 ET WesternU College of Veterinary Medicine professors featured in documentary on vegan dog food
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Jan 22, 2025, 13:05 ET ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
advisors to ImaginAb on the transaction. About ImaginAb, Inc. ImaginAb, Inc. is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies
More news about: ImaginAb, Inc.
Jan 22, 2025, 12:55 ET ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
advisors to ImaginAb on the transaction. About ImaginAb, Inc. ImaginAb, Inc. is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies
More news about: ImaginAb, Inc.
Jan 22, 2025, 11:30 ET Swiss startup Risklick launches AI-based software for medical device clinical trials
revolutionize the field of clinical trials and ultimately improve the lives of millions of patients worldwide. With Debiopharm, a leading biotechnology company in French-speaking Switzerland, ISS AG, Integrated Scientific Services,
More news about: Risklick Ltd.
Jan 22, 2025, 11:12 ET Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
/PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome
More news about: Cellipont Bioservices
Jan 22, 2025, 10:15 ET Oligonucleotide CDMO Market to Hit US$6.73 Billion by 2029 with 21.8% CAGR | MarketsandMarkets™
North America dominated the oligonucleotide CDMO market, driven by its advanced pharmaceutical infrastructure, high concentration of biotechnology firms, and substantial R&D investments in oligonucleotide therapeutics. The region benefits from a robust regulatory framework supporting innovation
More news about: MarketsandMarkets
Jan 22, 2025, 10:01 ET Veterinary Vaccines Market to Hit US$13.33 Billion by 2029 with 6.1% CAGR | MarketsandMarkets™
Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu Biotechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu
More news about: MarketsandMarkets
Jan 22, 2025, 09:00 ET Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
every stage of disease and deliver renewed hope for patients worldwide." ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, also
More news about: USA News Group
Jan 22, 2025, 08:08 ET Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
Mass., Jan. 22, 2025 /PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical
More news about: Artax Biopharma
Jan 22, 2025, 08:05 ET Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
the official views of the National Institutes of Health. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jan 22, 2025, 08:00 ET Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Jan 22, 2025, 08:00 ET Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape
backed by a star-studded strategic advisory board, including Robert S. Langer, founder of Moderna and over 40 other biotechnology companies, and Tim Garnett, former CMO of Eli Lilly, amongst others.
More news about: Lindus Health
Jan 22, 2025, 07:00 ET Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Jan 22, 2025, 01:43 ET Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks
Bioscience Hyundai ADM Bio is a subsidiary of Hyundai Bioscience, is a biotechnology company that develops anticancer drugs and also a Clinical Research Organization (CRO) service company in South Korea.
More news about: Hyundai ADM Bio
Jan 22, 2025, 00:08 ET Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East
DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition,
More news about: Anbio Biotechnology
Jan 21, 2025, 14:25 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
[Click here for information about joining the class action] Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the
More news about: Pomerantz LLP
Jan 21, 2025, 13:26 ET Theromics Inc. Appoints Experienced Industry Leader Dr. Suman Lal as Chief Executive Officer
BRIDGEWATER, Mass., Jan. 21, 2025 /PRNewswire/ -- Theromics Inc., a biotechnology company developing next-generation thermal accelerant technologies for enhanced ablation procedures and more precise and effective drug delivery,
More news about: Theromics Inc.
Jan 21, 2025, 13:04 ET Rion M. Vaughan Joins Rubin and Rudman's Bankruptcy and Creditors' Rights Practice Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Jan 21, 2025, 10:31 ET Intelligent Transportation System Market Skyrockets to $66.35 Billion by 2031 Dominated by Tech Giants - Hitachi, Siemens, DENSO and Cisco Systems, Inc. | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Logo:
More news about: The Insight Partners
Jan 21, 2025, 10:14 ET Tissue Engineering Market Is Projected To Reach $7.41 Billion by 2031, At A CAGR of 18.6% During The Forecast Period 2024-2031. (Analysis, Outlook, Leaders, Trends, Forecast, Segmentation, Market Growth Rate, Value) - Report By Meticulous Research®
This segment's growth is driven by the rising prevalence of cardiovascular diseases globally, increased R&D activities by pharmaceutical and biotechnology companies focused on developing stem cell therapies, and advancements in tissue engineering technologies. Based on end user, the global tissue
More news about: Meticulous Market Research Pvt. Ltd.